Latest news with #Rybelsus
Yahoo
22-05-2025
- Business
- Yahoo
Semaglutide (Ozempic, Wegovy, Rybelsus) Market Trends Analysis and Growth Report 2025-2035: Emerging Markets and Oral Formulations Present New Frontiers for Expansion
The Semaglutide Market, valued at USD 28.43 Billion in 2024, is anticipated to reach USD 93.60 Billion by 2035, growing at a CAGR of 10.47%. Growth drivers include the rising prevalence of diabetes and obesity, regulatory approvals, and expanding clinical indications. Key players like Novo Nordisk lead the market, which is influenced by patent protection and competitive dynamics in drug formulations. Semaglutide Market Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Market Size, Share & Trends Analysis Report by Product (Ozempic, Wegovy, Rybelsus), Application (Type 2 Diabetes Mellitus, Obesity), Route of Administration, Distribution Channel, Region, and Segment Forecasts, 2025 - 2035" report has been added to semaglutide industry is experiencing growth, driven by the increasing prevalence of diabetes and obesity worldwide. The rising demand for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes management has positioned semaglutide as a key therapeutic option. The market is influenced by regulatory approvals, expansion in clinical indications, and growing healthcare expenditures that support the adoption of advanced diabetes and obesity treatments. The primary drivers of the market for semaglutide include the increasing burden of type 2 diabetes and obesity, which have escalated the demand for effective therapeutic interventions. The drug's efficacy in reducing cardiovascular risks and aiding weight management has led to expanded usage beyond diabetes treatment. Additionally, favorable reimbursement policies and the growing adoption of self-administered injectable therapies contribute to market growth. Continuous research and development (R&D) activities aimed at improving drug delivery mechanisms further enhance its commercial market presents opportunities for expansion in emerging economies due to rising healthcare infrastructure investments and increasing awareness of diabetes management. There is also potential for further market penetration in obesity treatment, as semaglutide has demonstrated efficacy in weight reduction, leading to regulatory approvals in multiple regions. Pharmaceutical companies are actively exploring novel formulations, including oral versions and combination therapies, to enhance patient compliance and broaden market semaglutide industry is characterized by high R&D investment, stringent regulatory oversight, and strong intellectual property protection. Leading pharmaceutical firms dominate the landscape, leveraging extensive distribution networks and partnerships to expand their market presence. The competitive environment is shaped by ongoing clinical trials, product lifecycle management strategies, and efforts to differentiate products through formulation advancements and expanded is protected by multiple patents that cover its formulation, manufacturing process, and therapeutic applications. The primary patent for semaglutide extends into the 2030s, limiting generic competition and ensuring continued market exclusivity for key manufacturers. Companies investing in alternative formulations, such as oral and extended-release versions, seek additional patent protections to extend commercial viability beyond initial expiration market instances include regulatory approvals for semaglutide in new therapeutic areas, such as obesity treatment, which has significantly expanded its commercial potential. Market leaders have also engaged in strategic collaborations and acquisitions to strengthen distribution capabilities. Additionally, clinical trial results demonstrating superior efficacy compared to existing therapies have reinforced market adoption and driven further investment in next-generation semaglutide industry is poised for sustained growth, supported by increasing diabetes and obesity prevalence, technological advancements in drug delivery, and ongoing R&D initiatives. While patent protections ensure near-term market exclusivity, competitive dynamics may shift as alternative formulations and combination therapies emerge. Industry participants continue to focus on expanding indications and geographic reach to capitalize on the evolving market Market Report Highlights Based on product, Ozempic dominated the market with a revenue share of 59.62% in 2024, driven by strong clinical efficacy, broad regulatory approvals, and increasing adoption for type 2 diabetes. Based on application, Type 2 Diabetes Mellitus dominated the market and accounted for a revenue share of 71.16% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies. Based on route of administration, parenteral route of administration dominated the market and accounted for a share of 88.46% in 2024, driven by the widespread adoption of Ozempic and Wegovy, both available as injectable formulations. Based on distribution channel, retail pharmacies led the market and accounted for a share of 55.09% in 2024, driven by increasing consumer demand for GLP-1 receptor agonists like Ozempic and Wegovy. Key market players include Novo Nordisk, Eli Lilly, Viking Therapeutics, Lexicon Pharmaceuticals, Biocon, and AstraZeneca. Competition is expected to intensify as biosimilar manufacturers enter the market after semaglutide's patent expires. In March 2025, Novo Nordisk's phase 3b STRIDE trial showed that Ozempic (semaglutide 1.0 mg) improved walking distance by 13% in adults with type 2 diabetes and PAD. Results were presented at ACC 2025 and published in The Lancet. Novo Nordisk has submitted a label extension application to the EMA and FDA. Why Should You Buy This Report? Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover the pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Company Profiles Novo Nordisk Eli Lilly Viking Therapeutics Lexicon Pharmaceuticals Biocon AstraZeneca Key Attributes: Report Attribute Details No. of Pages 100 Forecast Period 2024 - 2035 Estimated Market Value (USD) in 2024 $28.43 Billion Forecasted Market Value (USD) by 2035 $93.6 Billion Compound Annual Growth Rate 10.4% Regions Covered Global Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Snapshot2.2. Segment Snapshot2.3. Competitive Landscape SnapshotChapter 3. Semaglutide Market Variables, Trends, & Scope3.1. Market Lineage Outlook3.2. Market Dynamics3.2.1. Market Driver Analysis3.2.2. Market Restraint Analysis3.3. Business Environment Analysis3.3.1. Industry Analysis - Porter's Five Forces Analysis3.3.2. PESTLE Analysis3.3.3. Pipeline Analysis, by Phase3.3.4. Patent Expiry Analysis3.3.5. Pricing Analysis3.3.6. Competitive Landscape: Emerging Biosimilars in The Post-Patent Semaglutide MarketChapter 4. Semaglutide Market: Product Business Analysis4.1. Product Market Share, 2024 & 20354.2. Product Segment Dashboard4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2035 (USD Million)4.4. Ozempic4.5. Wegovy4.6. Rybelsus4.7. OthersChapter 5. Semaglutide Market: Application Business Analysis5.1. Application Market Share, 2024 & 20355.2. Application Segment Dashboard5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2035 (USD Million)5.4. Type 2 Diabetes Mellitus5.5. Obesity5.6. OthersChapter 6. Semaglutide Market: Route of Administration Business Analysis6.1. Route of Administration Market Share, 2024 & 20356.2. Route of Administration Segment Dashboard6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2035 (USD Million)6.4. Parenteral6.5. OralChapter 7. Semaglutide Market: Distribution Channel Business Analysis7.1. Distribution Channel Market Share, 2024 & 20357.2. Distribution Channel Segment Dashboard7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2035 (USD Million)7.4. Hospital Pharmacies7.5. Retail Pharmacies7.6. Online PharmaciesChapter 8. Semaglutide Market: Regional Estimates & Trend Analysis8.1. Regional Market Share Analysis, 2024 & 20358.2. Regional Market Dashboard8.3. Market Size & Forecasts Trend AnalysisChapter 9. Competitive Landscape9.1. Participant Overview9.2. Company Market Position Analysis9.3. Company Categorization9.4. Strategy Mapping For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Semaglutide Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
20-05-2025
- Business
- Yahoo
Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement
Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership and board of directors. Per the press release, Lars Fruergaard Jørgensen will step down as CEO of Novo Nordisk following a mutual agreement with the company's board. He will remain in the role for a transitional period to ensure a smooth handover to new leadership. The search for his successor is currently underway, with an official announcement expected later. In connection with the leadership transition, Lars Rebien Sørensen, Chair of the Novo Nordisk Foundation and former CEO of NVO, will initially join the company's board as an observer, to be nominated for election as a board member at the Annual General Meeting in 2026. Lars Fruergaard Jørgensen was appointed to the CEO role in 2017. The company's remarkable success during Jørgensen's tenure resulted from the growing popularity of the obesity market. Novo Nordisk's semaglutide, a GLP-1 agonist, medicines gained significant traction, capturing a dominant share of the market. Among the most notable products are Ozempic injection and Rybelsus oral pill for type 2 diabetes (T2D), and Wegovy, an injection for weight management. Ozempic is also indicated for treating chronic kidney disease and Wegovy received FDA approval last year to reduce the risk of heart disease. Despite this success, recent market challenges and a decline in the company's share price since mid-2024 prompted the Novo Nordisk Foundation Board to initiate discussions around a change in leadership. Consequently, Novo Nordisk's board and Jørgensen mutually agreed that a leadership transition would be in the best interest of the company and its shareholders. Year to date, NVO shares have plunged 25.2% compared with the industry's 5.2% decline. Image Source: Zacks Investment Research The recent market challenges that caused Novo Nordisk's shares to fall steeply include tremendous competition in the obesity market from its arch-rival, Eli Lilly LLY, pipeline and regulatory setbacks, as well as the rise of compounding pharmacies offering low-cost alternatives to its flagship drugs amid supply challenges in 2024. NVO's semaglutide drugs have only been off the FDA's supply shortage list since February 2025. Lilly markets its tirzepatide injections, Mounjaro for T2D, and Zepbound for obesity. Lilly has also been taking significant strides in developing oral therapies for obesity, effectively putting pressure on Novo Nordisk. In April 2025, LLY reported first phase III success for its oral GLP-1 candidate, orforglipron, in lowering blood glucose and promoting weight loss in T2D patients. Lilly's orforglipron also showed significant weight reduction potential in the late-stage study. Oral obesity pills are easier to use compared to injections, which can improve patient adherence. Several other companies like Amgen AMGN and Viking Therapeutics VKTX are also making rapid progress in developing GLP-1-based candidates in their clinical pipeline. Amgen has begun a broad phase III program on its dual GIPR/GLP-1 receptor agonist, MariTide, across obesity, obesity-related conditions and T2D, with the first two phase III studies initiated in March. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for treating obesity. Phase III studies with the subcutaneous formulation of VK2735 are on track to begin in the second quarter. AMGN and VKTX's products can pose strong competition to Mounjaro/Zepbound and NVO's Ozempic/Wegovy in the future. Despite the leadership change at Novo Nordisk causing the stock price to stumble, a 10.4% increase in the company's stock price has been observed over the past month. Several factors related to its pipeline, regulatory updates and sector-specific developments have contributed to the same. A key catalyst was Novo Nordisk's recent $2.2 billion exclusive global collaboration and licensing deal with Septerna for developing and commercializing oral small-molecule medicines for treating obesity, T2D and other cardiometabolic diseases. With this collaboration deal, Novo Nordisk aims to expand its presence in the highly competitive obesity treatment market. To tackle the increasing competitive pressure in the industry and to diversify from its injectable GLP-1 products, including Wegovy and Ozempic, NVO is rapidly developing new obesity treatments to retain its edge, especially in the lucrative U.S. market. Earlier this month, the FDA accepted for review Novo Nordisk's regulatory application seeking the approval of oral semaglutide 25 mg for obesity. A final decision from the regulatory body is expected around the turn of the year. Meanwhile, CVS Caremark, a major pharmacy benefit manager, recently announced that it would make Novo Nordisk's Wegovy its preferred GLP-1 therapy for weight loss, effective July 1. NVO also announced partnerships with telehealth providers Hims & Hers Health to offer Wegovy at a discounted price to cash-paying patients. These are likely to give the company a commercial advantage over Lilly in the obesity market. Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote Novo Nordisk currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?
Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company's pipeline, regulatory updates and sector-specific developments have contributed to the much-awaited uptrend in the stock price. A key catalyst was Novo Nordisk's recent $2.2 billion exclusive global collaboration and licensing deal with Septerna for developing and commercializing oral small-molecule medicines for treating obesity, type II diabetes (T2D) and other cardiometabolic diseases. With this collaboration deal, Novo Nordisk aims to expand its presence in the highly competitive obesity treatment market. Novo Nordisk faces significant competition in the diabetes and obesity care market from its arch-rival Eli Lilly LLY, which markets its tirzepatide injections, Mounjaro for T2D, and Zepbound for obesity. To tackle the same and to diversify from its injectable GLP-1 products, including Wegovy and Ozempic (semaglutide), NVO is rapidly developing new obesity treatments to stay ahead, especially in the lucrative U.S. market. Earlier this month, the FDA accepted for review Novo Nordisk's regulatory application seeking the approval of oral semaglutide 25 mg for obesity. A final decision from the regulatory body is expected around the turn of the year. Oral obesity pills are easier to use compared to injections, which can improve patient adherence. Meanwhile, CVS Caremark, a major pharmacy benefit manager, recently announced that it would make Novo Nordisk's Wegovy its preferred GLP-1 therapy for weight loss, effective July 1. NVO also announced partnerships with telehealth providers Hims & Hers Health to offer Wegovy at a discounted price to cash-paying patients. These are likely to give the company a commercial advantage over Lilly in the obesity market, contributing to the share price increase. From a macroeconomic perspective, the broader market rally amid easing of trade tensions between the United States and China also contributed to drug stocks' rise. However, investors are advised not to jump to conclusions regarding acquiring/retaining the stock in their portfolio without considering the full spectrum of information available on Novo Nordisk. The company has faced several pipeline setbacks in the recent past. The competition in the obesity marketplace has also heated up significantly in the past couple of years, which threatens NVO's prowess in the market. Let's dig deeper and understand the company's strengths and weaknesses to better understand how to play the stock after the recent price rise. NVO's success in the past few years is underscored by its marketed semaglutide (GLP-1 agonist) medicines. The company has a strong presence in the Diabetes care market, with one of the broadest diabetes portfolios in the industry. Its global diabetes value market share as of March-end stands at 33.3%, fueled by Rybelsus, Ozempic and Victoza, putting up a strong performance. Novo Nordisk continues to be the global market leader in the GLP-1 segment, with around 54% value market share as of the end of the first quarter of 2025. Wegovy is a significant contributor to Novo Nordisk's revenues. Wegovy revenues surged 83% to DKK 17.4 billion in first-quarter 2025 due to strong prescription growth, driving higher revenues and profits. Additionally, Ozempic sales are also contributing positively to overall revenues. The company has also been investing heavily to expand its manufacturing capacity as part of its strategic move to entrench its diabetes and obesity care market leadership for its GLP-1 products. Novo Nordisk is pursuing new indications for semaglutide, including label expansions for Wegovy in additional cardiovascular conditions and for Ozempic in T2D patients with chronic kidney disease. It has also filed regulatory applications for Rybelsus to prevent serious cardiac events in T2D patients in both the United States and the EU, and is investigating semaglutide's potential in metabolic dysfunction–associated steatohepatitis. These efforts could expand the eligible patient population for semaglutide. Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio by developing Mim8 for hemophilia A, with plans to submit it for regulatory approval soon. Alhemo (concizumab) has been approved in the EU for treating haemophilia A or B with inhibitors. Alhemo is not approved in the United States. Despite the minor stock price recovery in the past month, NVO's pipeline and regulatory setbacks have resulted in the stock crashing 33.7% in the past six months. The company reported disappointing data from two late-stage studies for its next-generation subcutaneous obesity candidate, CagriSema, a follow-up drug to Wegovy. In these studies, CagriSema demonstrated a lower-than-expected reduction in body weight. Last month, Medicare announced that it will not cover costly weight-loss drugs, such as NVO's Wegovy (semaglutide) and Lilly's Zepbound (tirzepatide), as obesity remains unclassified as a disease. Consequently, these medications, often viewed as cosmetic, may become less accessible to patients. Competition in the obesity market is heating up as the obesity market is expected to expand to $100 billion by 2030, according to data from Goldman Sachs. Lilly and Novo Nordisk presently dominate the market. Lilly has also been taking significant strides in the development of oral therapies for obesity, effectively putting pressure on Novo Nordisk. In April 2025, LLY reported first phase III success for its oral GLP-1 candidate, orforglipron, in lowering blood glucose and promoting weight loss in T2D patients. Lilly's orforglipron has also shown significant weight reduction potential in the late-stage study. Several other companies like Amgen AMGN and Viking Therapeutics VKTX are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Amgen has begun a broad phase III program on its dual GIPR/GLP-1 receptor agonist, MariTide, across obesity, obesity-related conditions and T2D, with the first two phase III studies initiated in March. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Phase III studies with the subcutaneous formulation of VK2735 are on track to begin in the second quarter. AMGN and VKTX's products can pose strong competition to Mounjaro/Zepbound and NVO's Ozempic/Wegovy in the future. Year to date, Novo Nordisk shares have plunged 23.1% compared with the industry's decline of 8.8%. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading below both its 50 and 200-day moving averages. Image Source: Zacks Investment Research Novo Nordisk is trading at a slight premium to the industry, as seen in the chart below. Going by the price/earnings ratio, the company's shares currently trade at 15.78 forward earnings, which is higher than 14.06 for the industry. However, the stock is trading much below its five-year mean of 29.25. Image Source: Zacks Investment Research Earnings estimates for 2025 have improved from $3.80 to $3.85 per share over the past 30 days. During the same time frame, Novo Nordisk's 2026 earnings per share estimates have improved from $4.60 to $4.65. Image Source: Zacks Investment Research The stock's return on equity on a trailing 12-month basis is 80.95%, which is higher than 32.84% for the large drugmaker industry, as seen in the chart below. Image Source: Zacks Investment Research Novo Nordisk, currently carrying a Zacks Rank #3 (Hold), has the potential to boost shareholders' wealth in the future. Despite past pipeline and regulatory setbacks, coupled with macroeconomic uncertainties, we remain confident that NVO is a good stock to retain. The company operates in a lucrative market that is rapidly expanding. Its strong year-over-year revenues and profits, fueled by rising demand for Wegovy and Ozempic, suggest long-term potential. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The company is actively working to expand the approved uses of its key products, Wegovy, Ozempic, and Rybelsus, which could significantly increase the eligible patient pool and drive future revenues. The FDA's removal of semaglutide from its shortage list and recent price reductions for Wegovy are also expected to improve access and support sales growth. However, Eli Lilly remains a formidable adversary in the obesity market space, which threatens NVO's market share. Several large drugmakers like Roche, Merck and AbbVie are also looking to enter into the obesity space by in-licensing obesity candidates from smaller biotechs, which could significantly increase competition in the market. Novo Nordisk is developing new obesity treatments to retain its edge, especially in the U.S. market. Hence, we can conclude that the recent uptrend in the stock price can be interpreted as an improvement in conditions for Novo Nordisk, as is supported by the upward estimate revisions. Investors who already own the stock should hold their position for long-term gains. Short-term investors are, however, advised to steer clear of the stock to avoid near-term volatility. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year
Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for the blockbuster drugs Ozempic and Wegovy, the company said Friday. The move follows a 50%+ decline in Novo's share price and increasing pressure from the powerful Novo Nordisk Foundation, which controls the company's voting majority. Jørgensen, who joined Novo in 1991 and became CEO in 2017, will stay on for a transition period. A search for his successor is underway. During his tenure, Novo Nordisk became Europe's most valuable company — at one point surpassing LVMH — thanks to skyrocketing sales of semaglutide, the active ingredient in Ozempic (for type 2 diabetes) and Wegovy (for weight loss). Both belong to the GLP-1 class of drugs, which regulate blood sugar and suppress appetite. For a stretch, the growth was nothing short of eye-popping. Since its 2017 debut, Ozempic alone grew into a $13 billion-a-year drug, while Wegovy, which was approved in 2021, became a $4.5 billion blockbuster in just two years. Together, Novo's GLP-1 therapies helped drive one of the fastest commercial expansions in pharmaceutical history, transforming the company from a niche diabetes firm into a global superpower. Demand was so intense that Novo was forced to pause its advertising in 2023 because of supply shortages. At the height of the craze, Jørgensen told Bloomberg that he was fielding calls from food company CEOs, so scared were they by the weight-reducing possibility of the new drugs. Hollywood gossip and everyday cocktail party chatter became dominated by speculation about who's on Ozempic and who's trying to track down their own supply. Novo's oral version, Rybelsus, became another effective addition to its portfolio, while legacy insulin brands like NovoLog and Tresiba helped the company maintain its dominance in diabetes care. But Novo Nordisk's fortunes have notably shifted over the past year. Shares fell 50%+ amid mounting competition from Eli Lilly (LLY), underwhelming trial results for next-gen therapy CagriSema, and growing investor skepticism about just how big the GLP-1 market can get. Wall Street's initial burst of enthusiasm regarding weight-loss drugs has cooled off considerably. Novo's Q1 report, which was released on May 7 and lowered growth expectations on 'lower-than-planned penetration of branded GLP-1 treatments in the US,' failed to reverse the trend. Likewise, Friday's announcement seems only to have further spooked markets. Novo shares fell around 5% in Copenhagen trading, with its U.S. ADRs dropping a corresponding 5% premarket. Eli Lilly stock, for its part, rose 1.3%. The Novo Nordisk Foundation also signaled a desire for more control going forward. Foundation chair and former CEO Lars Rebien Sørensen will begin attending board meetings immediately, with plans for formal election in 2026. For the latest news, Facebook, Twitter and Instagram.
Reuters
15-05-2025
- Business
- Reuters
Abbott India's quarterly profit climbs 28% on strong demand
May 15 (Reuters) - Drugmaker Abbott India ( opens new tab reported a 28% rise in fourth-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications. The company, known for its PediaSure nutrition drink, reported a profit of 3.67 billion rupees ($43 million) for the quarter ended March 31, up from 2.87 billion rupees a year ago. Revenue from operations climbed 11.5% to 16.05 billion rupees. For further highlights, click. Anti-diabetic, cardiovascular and gastrointestinal drugs, which form a major chunk of Abbott India's drugs portfolio, saw the highest demand during the quarter, Elara Capital said. Moreover, strong demand for Rybelsus, the oral version of Novo Nordisk's ( opens new tab blockbuster weight-loss drug semaglutide distributed by Abbott in India, also boosted sales, analysts said. Peer JB Chem and Pharma also reported higher quarterly profit on strong demand for its gastrointestinal drugs. PEER COMPARISON * Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell ** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT JANUARY TO MARCH STOCK PERFORMANCE -- All data from LSEG -- $1 = 85.4620 Indian rupees
